Subsense

Executive Summary

Subsense is a neurotechnology company pioneering a non-surgical, bidirectional brain-computer interface (BCI) platform. Its core technology combines intranasally administered nanoparticles with a wearable headset to read and stimulate neural activity, offering a less invasive alternative to traditional implanted BCIs. The company is initially targeting neurological disorders such as Parkinson's disease and epilepsy, aiming to provide therapeutic modulation of neural circuits without the risks associated with open-brain surgery. This approach could significantly expand the addressable patient population and reduce barriers to adoption in clinical settings. However, the technology is still in early development, and key challenges include nanoparticle biocompatibility, long-term safety, and regulatory approval.

Upcoming Catalysts (preview)

• H2 2026Initiation of First-in-Human Clinical Trial for Parkinson's Disease30% success
• Q1 2027Strategic Partnership with a Pharmaceutical Company for Epilepsy Indication20% success
• Q4 2026Series A Funding Round to Support Manufacturing Scale-Up50% success